15 Years of Clinical Experience With Bupropion HCl

• DOI: 10.4088/pcc.v07n0305
• Publication Date: 2009-07-20T19:14:32Z
• Authors: Maurizio Fava; A. John Rush; Michael E. Thase; Anita Clayton; Stephen M. Stahl; James F. Pradko; J. Andrew Johnston
• Keywords: Bupropion; Somnolence

Bupropion has been available in the United States since 1989. Initially a thrice-daily immediate-release formulation, twice-daily sustained-release formulation followed 1996, and, August 2003, once-daily extended-release was introduced. On 15th anniversary of its introduction, we undertook review background/history, mechanism action, formulations, and clinical profile bupropion.Major efficacy trials other reports were obtained reviewed from MEDLINE searches, abstracts professional meetings, bupropion SR manufacturer's databases. Searches English-language articles conducted June 2003 through 2004. No time limit specified which using search terms bupropion, SR, XL.Bupropion inhibits re-uptake norepinephrine dopamine neurotransmission without any significant direct effects on serotonin neurotransmission. is an effective antidepressant with comparable to selective reuptake inhibitors antidepressants. It well tolerated short-and longer-term treatment. Headache, dry mouth, nausea, insomnia, constipation, dizziness are most common adverse events. Seizure allergic reactions medically important events associated reported rarely. Among all newer antidepressants States, appears have among lowest incidence sexual dysfunction, weight gain, somnolence. Although not U.S. Food Drug Administration approved for these indications, also used as adjunctive treatment reverse antidepressant-induced dysfunction augment anti-depressant partial responders non-responders agents.Bupropion played will continue play role major depressive disorder adults, related disorders.